Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab in Active Systemic Lupus Erythematosus (Phase 3)
CTR20191493Phase 3Terminated
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of ustekinumab in systemic lupus erythematosus (SLE), sponsored by Janssen Pharmaceutical. Started Jul 2019; status: terminated.
02
Drugs
ustekinumab
03
Conditions
systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on CTR20191493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191493.